Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental migraine drug JS010 takes first step in human safety trial

NCT ID NCT06158737

Completed Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This Phase 1 trial evaluates the safety, tolerability, and how the body processes a single dose of JS010 injection in healthy adults aged 18 to 45. Participants receive one of six dose levels or a placebo to assess side effects and drug levels in the blood. The goal is to gather early safety data before testing JS010 as a potential migraine preventive treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called JS010 injection
What this could lead to
If successful, this could lead to a new preventive treatment for migraines.
What could go wrong
This is an early Phase 1 trial in healthy people, so it may not work for migraine patients or may have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.